A Potential Role for Targeted Blood Biomarker Profiling
The general purpose of our translational research studies is to identify clinical tools for the detection of subclinical parenchymal lung disease. Our present studies focus on identifying peripheral blood biomarkers that could aid in the detection of subclinical interstitial lung disease and risk-stratify subjects at risk of developing pulmonary fibrosis.
Ivan O. Rosas, MD
Assistant Professor of Medicine at Harvard Medical School; Director of the Interstitial Lung Disease Program at Brigham and Women’s Hospital; Director of the Pulmonary Fibrosis Research Program at Lovelace Respiratory Research Institute
Dr. Rosas completed his Pulmonary and Critical Care Fellowship training at Johns Hopkins Hospital and a Research Fellowship at the National Heart Lung and Blood Institute Intramural Program.
Dr. Rosas’ translational research program focuses on identifying novel molecular targets for diagnosis and treatment of pulmonary fibrosis and the development of strategies to prevent the development of interstitial lung disease in at risk populations.
- The rationale for early detection of Pulmonary Fibrosis
- Phenotypic characteristics of Subclinical Interstitial Lung Disease (ILD) in at risk populations
- A strategy to select blood biomarkers for Subclinical ILD
- How our translational research studies can improve the diagnosis and treatment of ILD
Researchers interested in the application of biomarkers in the following fields:
- Pulmonary Disease
- Translational Medicine
- 03 Sep 2014
- Cardiovascular, Webinars